PepGuide

Dual GIP/GLP-1 receptor agonist peptide

Tirzepatide

A dual GIP/GLP-1 agonist with among the strongest weight-loss results reported in pivotal obesity trials.

Evidence:
Strong human evidence
Status:
FDA-approved for specific labeled indications
Reviewed:
2026-08-03

Also known as: Tirzepatide, Tirz, Trz, Mounjaro, Zepbound, LY3298176, GLP-2, GL2TZ

What is Tirzepatide?

A dual GIP/GLP-1 agonist with among the strongest weight-loss results reported in pivotal obesity trials.

This profile is educational. It organizes publicly discussed research context for Tirzepatide and related naming aliases — it is not a treatment guide.

Proposed mechanism

Co-activates GIP and GLP-1 receptors; combined incretin signaling may produce greater metabolic effects than GLP-1 agonism alone.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Strong human evidence

Preclinical evidence grade: Strong human evidence

GL2TZ (tirzepatide) SURMOUNT trials reported up to ~22% mean weight loss at 72 weeks (SURMOUNT-1). SURPASS programs demonstrated robust HbA1c reductions in T2D. FDA approved as Mounjaro (T2D) and Zepbound (obesity). Available evidence suggests dual incretin activation is a meaningful advance, though head-to-head long-term comparisons with other agents continue. Human evidence is strong within labeled populations.

Key uncertainties

  • Mechanistic contribution of GIP vs GLP-1
  • Discontinuation effects

Research areas being studied

  • Obesity
  • Type 2 diabetes
  • Obstructive sleep apnea
  • MASH

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Decreased appetite

Additional risks & considerations

  • GI effects
  • Thyroid C-cell warnings
  • Investigation of aspiration risk with anesthesia

Regulatory status

FDA-approved for specific labeled indications

FDA approved for type 2 diabetes and chronic weight management.

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

What is Tirzepatide?

A dual GIP/GLP-1 agonist with among the strongest weight-loss results reported in pivotal obesity trials.

How does Tirzepatide work (proposed mechanism)?

Co-activates GIP and GLP-1 receptors; combined incretin signaling may produce greater metabolic effects than GLP-1 agonism alone.

What is Tirzepatide being researched for?

Tirzepatide has been discussed in research contexts including: Obesity, Type 2 diabetes, Obstructive sleep apnea, MASH.

What does current evidence say about Tirzepatide?

Strong human evidence. GL2TZ (tirzepatide) SURMOUNT trials reported up to ~22% mean weight loss at 72 weeks (SURMOUNT-1). SURPASS programs demonstrated robust HbA1c reductions in T2D. FDA approved as Mounjaro (T2D) and Zepbound (obesity). Available evidence suggests dual incretin activation is a meaningful advance, though head-to-head long-term comparisons with other agents continue. Human evidence is strong within labeled populations.

What safety considerations are noted for Tirzepatide?

Reported or discussed considerations include: Nausea; Diarrhea; Vomiting; Constipation; Decreased appetite; GI effects; Thyroid C-cell warnings; Investigation of aspiration risk with anesthesia. This is educational information, not medical advice.

Is Tirzepatide FDA approved?

FDA-approved for specific labeled indications. FDA approved for type 2 diabetes and chronic weight management.

References & sources

  • Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — NEJM. Evidence type: human.

Prefer interactive tools? Open the PepGuide library entry for Tirzepatide or ask PepGuide AI.

Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.